UBS Group reiterated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Wednesday, December 27th, 247wallst.com reports. The brokerage currently has a $56.51 price objective on the biotechnology company’s stock, down from their prior price objective of $76.00.
Several other research analysts have also weighed in on the company. Credit Suisse Group upped their price target on Sarepta Therapeutics from $5.65 to $81.00 and gave the company an outperform rating in a research report on Thursday, September 7th. Nomura reissued a buy rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. Zacks Investment Research raised Sarepta Therapeutics from a hold rating to a buy rating and set a $54.00 target price on the stock in a research report on Monday, October 30th. Needham & Company LLC reaffirmed a buy rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. Finally, Oppenheimer reaffirmed a buy rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $63.88.
Shares of Sarepta Therapeutics (SRPT) opened at $61.52 on Wednesday. The company has a market capitalization of $3,980.00, a price-to-earnings ratio of -30.16 and a beta of 1.37. Sarepta Therapeutics has a fifty-two week low of $26.26 and a fifty-two week high of $61.89. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.66. The firm had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the firm earned ($0.95) earnings per share. sell-side analysts anticipate that Sarepta Therapeutics will post -3.07 EPS for the current year.
In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Douglas S. Ingram bought 38,138 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the purchase, the chief executive officer now owns 420,196 shares in the company, valued at $22,035,078.24. The disclosure for this purchase can be found here. Corporate insiders own 9.60% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock valued at $143,572,000 after purchasing an additional 162,543 shares during the period. HealthCor Management L.P. boosted its stake in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after purchasing an additional 481,890 shares during the period. Jennison Associates LLC boosted its stake in Sarepta Therapeutics by 103.9% during the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock valued at $51,885,000 after purchasing an additional 582,894 shares during the period. Eagle Asset Management Inc. boosted its stake in Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock valued at $49,858,000 after purchasing an additional 207,810 shares during the period. Finally, Emerald Advisers Inc. PA boosted its stake in Sarepta Therapeutics by 2.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock valued at $40,528,000 after purchasing an additional 18,077 shares during the period. Hedge funds and other institutional investors own 82.02% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/14/ubs-group-reaffirms-outperform-rating-for-sarepta-therapeutics-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.